Current Report Filing (8-k)
April 20 2021 - 7:39AM
Edgar (US Regulatory)
0000001800
false
Common Shares, Without Par Value
ABT
0000001800
2021-04-20
2021-04-20
0000001800
us-gaap:CommonStockMember
exch:XCHI
2021-04-20
2021-04-20
0000001800
us-gaap:CommonStockMember
exch:XNYS
2021-04-20
2021-04-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Common Shares, Without Par Value
|
|
ABT
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
April 20, 2021
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in
charter)
Illinois
|
|
1-2189
|
|
36-0698440
|
(State or other Jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
100 Abbott Park Road
Abbott
Park, Illinois 60064-6400
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of
the Act:
Title of Each Class
|
Trading
Symbol(s)
|
Name of Each Exchange
on Which Registered
|
Common Shares, Without Par Value
|
ABT
|
New
York Stock Exchange
Chicago
Stock Exchange, Inc.
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02
|
Results of Operations and Financial Condition
|
On April 20, 2021, Abbott Laboratories announced its results of operations
for the first quarter 2021.
Furnished as Exhibit 99.1, and incorporated herein by reference,
is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures
including, among others, net earnings from continuing operations excluding specified items. These non-GAAP financial measures adjust
for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction
initiatives, certain litigation, the acquisition of an R&D asset, the impairment of certain assets, tax benefits associated with specified
items, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible
amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management
internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides
useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to
better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to
monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition
to, and not as a substitute for, financial measures prepared in accordance with GAAP.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES
|
|
|
Date:
April 20, 2021
|
By:
|
/s/
Robert E. Funck, Jr.
|
|
|
Robert E. Funck, Jr.
|
|
|
Executive Vice President, Finance and Chief Financial Officer
|
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024